India, Nov. 8 -- Johnson & Johnson (JNJ) reported encouraging first-in-human Phase 1 results for the investigational combination of pasritamig and JNJ-9401, two bispecific antibodies designed to work together to enhance the immune system's ability to target advanced prostate cancer.
At the recommended dosing regimen, 73% of treated patients achieved a prostate-specific antigen (PSA) reduction of at least 50%, while 47% experienced deep PSA declines of 90% or more. PSA is a key biomarker used to assess prostate cancer activity and treatment response.
The combination marks the first clinically evaluated dual-tumor-antigen-targeted bispecific antibody regimen in prostate cancer. The therapy simultaneously targets kallikrein-related peptidase...